Toshimitsu Yamaoka

ヤマオカトシミツ | Toshimitsu Yamaoka

Affiliation and department：

Research keywords (3)：薬剤耐性 , チロシンキナーゼ阻害剤 , EGFR

Research theme for competitive and other funds (6)：

2016 - 2019 Investigate the role of TNF and EGFR in the onset and progression of lung cancer complicated with COPD
2013 - 2016 The potential mechanisms of EGFR-TKI induced lung injury in mice model
2010 - 2014 The role of ADAM17 in squamous cell lung cancer
2011 - 2013 Elucidation of trans-activation mechanism from TRAIL receptor to EGFR
2011 - 2013 Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with advanced non-small cell lung cancer

Show all

Papers (68)：

Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Hironori Sagara. Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis. International journal of molecular sciences. 2023. 24. 3
Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Kensuke Higuchi, Yuki Hasebe, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Koichi Ando, Yusuke Kuroda, et al. Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer. Genes. 2022. 13. 12
山岡利光, 長谷部友紀, 眞鍋亮, 岸野康成, 楠本壮二郎, 安藤浩一, 大森亨, 相良博典, 鶴谷純司. 肺腺癌細胞PC-9におけるオシメルチニブの獲得耐性機序の検討. 肺癌. 2022. 62. 6. 753-753
西原成俊, 山岡利光, 長谷部友紀, 石川文博, 楠本壮二郎, 大森亨, 相良博典, 吉田仁, 鶴谷純司. 肺腺癌細胞における第3世代EGFR-TKIオシメルチニブの獲得耐性機序の検討(Resistance mechanisms against osimertinib in lung adenocarcinoma cells with EGFR-activating mutation). 日本癌学会総会記事. 2022. 81回. P-2365
Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Tohru Ohmori, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryo Manabe, Yuki Hasebe, Hironori Sagara, et al. Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation. Cells. 2022. 11. 14

ｍore...

MISC (183)：

山岡利光, 岸野康成, 楠本壮次郎, 安藤浩一, 大森亨, 相良博典, 鶴谷純司. 肺腺癌細胞PC-9における第3世代EGFR-TKI,オシメルチニブの獲得耐性機序の検討. 日本癌学会学術総会抄録集(Web). 2021. 80th
Toshimitsu Yamaoka, Ohba Motoi, Yasunari Kishino, Sojiro Kusumoto, Junji Tsurutani, Tohru Ohmori. KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR. CANCER RESEARCH. 2019. 79. 13
山岡利光, 岸野康成, 楠本壮二郎, 鶴谷純司, 相良博典, 大森亨. EGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株におけるオシメルチニブ獲得耐性機序. 日本呼吸器学会誌. 2019. 8. 増刊. 180-180
山岡利光, 岸野康成, 楠本壮二郎, 鶴谷純司, 相良博典, 大森亨. EGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株におけるオシメルチニブ獲得耐性機序. 日本呼吸器学会誌(Web). 2019. 8
山岡利光, 大森亨, 相良博典, 鶴谷純司. 野生型KRAS遺伝子増幅によるEGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株のオシメルチニブ獲得耐性機序. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2019. 23rd

ｍore...

Education (2)：

1998 - 2002 Showa University Guraduate School of Medical Sciences
1992 - 1998 Showa University School of Medicine

Professional career (1)：

Ph.D (Showa University)

Work history (8)：

2018/08 - 現在 Showa University Advanced Cancer Translational Institute Associate Professor
2017/12 - 2018/08 Showa University Institute of Molecular Oncology,Showa University
2011/10 - 2017/12 Showa University Institute of Molecular Oncology,Showa University
2011/09 - 2011/10 Showa University
2008/04 - 2011/08 昭和大学呼吸器・アレルギー内科助教

Show all

Awards (2)：

2017/06 - 昭和大学医学部同窓会平成29年度昭和大学医学部同窓会学術研究助成
2009/11 - 東京呼吸病態研究会第13回東京呼吸病態研究会優秀発表賞

Association Membership(s) (10)：

American Society of Clinical Oncology , American Association for Cancer Research , JAPANESE SOCIETY OF ALLERGOLOGY , 日本臨床腫瘍学会 , THE JAPAN LUNG CANCER SOCIETY , THE JAPANESE CANCER ASSOCIATION , THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER , THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY , THE JAPANESE RESPIRATORY SOCIETY , THE JAPANESE SOCIETY OF INTERNAL MEDICINE

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page